ANTIKREBSZUSAMMENSETZUNGEN

Patent europeic · EP3925598 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3925598
Numer da la dumonda
EP21175525
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
03-12-2015
Publitgà
22-12-2021
Concedì
12-02-2025
La protecziun finescha il pli tard
02-12-2035
Proxima taxa annuala scadenta
31-12-2026
Classas IPC
A61K 9/00 (2006.01)
A61K 9/14 (2006.01)
A61K 9/20 (2006.01)
A61K 31/4439 (2006.01)
A61P 35/00 (2006.01)
A61P 35/04 (2006.01)
Prioritad
EP 14196605 05.12.2014
Derivà da
EP15820351
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-01-2026

    Midada

    Published in Swissreg on 01.01.2026

  2. 24-12-2025

    Midada

    Published in Swissreg on 24.12.2025

  3. 24-03-2025

    Represchentant inscrit

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 24.03.2025

  4. 12-02-2025

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 12.02.2025

Partidas

Possessur

Aragon Pharmaceuticals, Inc.

10990 Wilshire Blvd. Suite 440, Los Angeles, CA 90024, US

Represchentant

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventur

VERRECK, Geert

Beerse, BE

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.